Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024
The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.
- The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.
- To register, click here.
- NRL-1004, an investigational nasal spray formulation of olanzapine and Neurelis proprietary Intravail® technology, for the treatment of acute agitation episodes, featuring Leslie Lucien Citrome, MD, MPH (New York Medical College, SUNY Upstate Medical University, Icahn School of Medicine at Mount Sinai).
- A live question and answer session will follow the formal presentations of both segments.